Abstract |
Pipobroman (PB) was tested in a prospective efficacy trial in 24 previously untreated patients with essential thrombocythemia and followed up for a median of 47 months (range, 12-120). Plateletpheresis was not done. Hematologic complete response (platelet count less than 450 X 10(9)/L for 3 consecutive months) was achieved in 92% of the cases, in a median time of 12 weeks (range, 2-22). However, continuous low-dose maintenance therapy with PB was necessary to avoid recurrences of the disease. Major thrombocythemia-related complications were observed in 20% of the cases; the 5-year overall and complication-free survival rates were 92% and 75%, respectively. No acute or chronic toxicity was observed; no drug-induced amenorrhea and subsequent acute leukemia occurred. PB does appear to be efficacious in essential thrombocythemia; however, the evaluation of its leukemogenic risk will await further experience.
|
Authors | E Brusamolino, A Canevari, L Salvaneschi, S Merante, C Bernasconi |
Journal | Cancer treatment reports
(Cancer Treat Rep)
Vol. 68
Issue 11
Pg. 1339-42
(Nov 1984)
ISSN: 0361-5960 [Print] United States |
PMID | 6541969
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
|
Chemical References |
|
Topics |
- Adult
- Aged
- Drug Evaluation
- Female
- Humans
- Male
- Middle Aged
- Pipobroman
(therapeutic use)
- Polycythemia Vera
(drug therapy)
- Prospective Studies
- Thrombocythemia, Essential
(drug therapy)
- Thrombocytosis
(drug therapy)
|